Subventions financées

New neuroimaging techniques enable us to measure the key hallmarks of Alzheimer’s disease (AD) pathology before symptoms appear.

Mr. Little’s current focus is on building computer software that can identify altered brain development patterns in fetal alcohol spectrum disorder (FASD) using brain images.

Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS) are two of the most common and devastating neurodegenerative diseases, affecting more than 2% of the population over the age of 65.

Brain disorders such as autism, major depressive disorder and Alzheimer’s disease are among the greatest medical challenges of our era.

New approaches in neurodevelopmental research increasingly seek to integrate enormous amounts of data through sophisticated informatics so as to determine the relationship between genotype and phenotypes, both structural and functional, as they change over time during development.

More than 1 in 100 individuals are diagnosed with Autism Spectrum Disorder (ASD), with profound impacts on the quality of life of those who are affected and their families.

Alzheimer’s Disease (AD) is a severe dementia that is likely a result of years of buildup in the brain of molecules called amyloid-beta oligomers (AβOs).

Synaptic plasticity is the process where the strength of connections between nerve cells is altered by experience.

Magnetic Seizure Therapy (MST) is a novel form of treatment that uses high intensity magnetic field pulses to stimulate the brain and induce a seizure as a therapeutic intervention for patients with depression resistant to antidepressant medication, known as Treatment Resistant Depression (TRD).

Parkinson’s Disease (PD) is a debilitating neurodegenerative disease for which there is no cure.